AstraZeneca PLC (AZN)vsHalozyme Therapeutics Inc (HALO)
AZN
AstraZeneca PLC
$160.17
+0.33%
HEALTHCARE · Cap: $252.33B
HALO
Halozyme Therapeutics Inc
$107.20
+0.19%
HEALTHCARE · Cap: $12.29B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 3588% more annual revenue ($61.37B vs $1.66B). HALO leads profitability with a 24.9% profit margin vs 17.0%. AZN trades at a lower P/E of 24.3x. HALO earns a higher WallStSmart Score of 72/100 (B).
AZN
Buy60
out of 100
Grade: C+
HALO
Strong Buy72
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Intrinsic value data unavailable for HALO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Every $100 of equity generates 288 in profit
Strong operational efficiency at 59.8%
Revenue surging 47.7% year-over-year
Keeps 25 of every $100 in revenue as profit
Earnings expanding 42.9% YoY
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
Premium valuation, high expectations priced in
Distress zone — elevated risk
Weak financial health signals
Trading at 85.1x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : HALO
The strongest argument for HALO centers on Return on Equity, Operating Margin, Revenue Growth. Profitability is solid with margins at 24.9% and operating margin at 59.8%. Revenue growth of 47.7% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : HALO
The primary concerns for HALO are P/E Ratio, Altman Z-Score, Piotroski F-Score. Debt-to-equity of 14.95 is elevated, increasing financial risk.
Key Dynamics to Monitor
AZN profiles as a mature stock while HALO is a growth play — different risk/reward profiles.
HALO carries more volatility with a beta of 0.88 — expect wider price swings.
HALO is growing revenue faster at 47.7% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
HALO scores higher overall (72/100 vs 60/100), backed by strong 24.9% margins and 47.7% revenue growth. AZN offers better value entry with a 18.4% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Halozyme Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company is headquartered in San Diego, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?